NVIDIA’s BioNeMo, a generative AI platform for drug discovery, is now accessible via Amazon Web Services (AWS). This initiative allows healthcare and life sciences developers to integrate NVIDIA-accelerated offerings, such as BioNeMo, into their AWS cloud resources. Techbio innovators like Alchemab Therapeutics, Basecamp Research, Character Biosciences, Evozyne, Etcembly and LabGenius are already using BioNeMo for AI-accelerated drug discovery. The platform includes pretrained large language models, data loaders and optimised training recipes to speed up drug candidate screening and protein structure prediction. BioNeMo’s models can be run on cloud-based high performance computing clusters.
“Researchers and developers at leading pharmaceutical and techbio companies can now easily deploy NVIDIA Clara software and services for accelerated healthcare through Amazon Web Services.”
NVIDIA BioNeMo: A New Tool for Drug Discovery on AWS
NVIDIA, a multinational technology company, has announced that its Clara healthcare suite, including BioNeMo, is now accessible via Amazon Web Services (AWS). This initiative was announced at AWS re:Invent and is aimed at researchers and developers at pharmaceutical and techbio companies. The goal is to provide these professionals with the ability to easily deploy NVIDIA Clara software and services for accelerated healthcare through AWS.
BioNeMo is a generative AI platform for drug discovery that is currently available via the AWS ParallelCluster cluster management tool for high performance computing and the Amazon SageMaker machine learning service. It will soon be coming to NVIDIA DGX Cloud on AWS. This platform allows companies to build or customize digital biology foundation models with proprietary data, scaling up model training and deployment using NVIDIA GPU-accelerated cloud servers on AWS.
Techbio Innovators and BioNeMo
Several techbio innovators, including Alchemab Therapeutics, Basecamp Research, Character Biosciences, Evozyne, Etcembly, and LabGenius, are already using BioNeMo for generative AI-accelerated drug discovery and development. This collaboration provides these companies with more ways to rapidly scale up cloud computing resources for developing generative AI models trained on biomolecular data.
This announcement extends NVIDIA’s existing healthcare-focused offerings available on AWS. These include NVIDIA MONAI for medical imaging workflows and NVIDIA Parabricks for accelerated genomics.
BioNeMo is a domain-specific framework for digital biology generative AI. It includes pretrained large language models (LLMs), data loaders, and optimized training recipes. These tools can help advance computer-aided drug discovery by speeding up target identification, protein structure prediction, and drug candidate screening.
ESM-2: A Powerful Model for Protein Structure Prediction
One of the models available through BioNeMo is ESM-2, a powerful LLM that supports protein structure prediction. This model achieves almost linear scaling on 256 NVIDIA H100 Tensor Core GPUs. Researchers can scale to 512 H100 GPUs to complete training in a few days instead of a month, the training time published in the original paper.
BioNeMo’s Pretrained Models and Optimized Training Recipes
BioNeMo’s pretrained models and optimized training recipes are available using self-managed services like AWS ParallelCluster and Amazon ECS. They are also available through integrated, managed services through NVIDIA DGX Cloud and Amazon SageMaker. These tools can help R&D teams build foundation models that can explore more drug candidates, optimize wet lab experimentation, and find promising clinical candidates faster.
“Thousands of healthcare and life sciences companies globally use AWS. They will now be able to access BioNeMo to build or customize digital biology foundation models with proprietary data, scaling up model training and deployment using NVIDIA GPU-accelerated cloud servers on AWS.”
“Techbio innovators including Alchemab Therapeutics, Basecamp Research, Character Biosciences, Evozyne, Etcembly and LabGenius are among the AWS users already using BioNeMo for generative AI-accelerated drug discovery and development. This collaboration gives them more ways to rapidly scale up cloud computing resources for developing generative AI models trained on biomolecular data.”
“BioNeMo is a domain-specific framework for digital biology generative AI, including pretrained large language models (LLMs), data loaders and optimized training recipes that can help advance computer-aided drug discovery by speeding target identification, protein structure prediction and drug candidate screening.”
Developers can train ESM-2 at scale using checkpoints of 650 million or 3 billion parameters. Additional AI models supported in the BioNeMo training framework include small-molecule generative model MegaMolBART and protein sequence generation model ProtT5.
BioNeMo’s pretrained models and optimized training recipes — which are available using self-managed services like AWS ParallelCluster and Amazon ECS as well as integrated, managed services through NVIDIA DGX Cloud and Amazon SageMaker — can help R&D teams build foundation models that can explore more drug candidates, optimize wet lab experimentation and find promising clinical candidates faster.
Summary
NVIDIA’s BioNeMo, a generative AI platform for drug discovery, is now accessible through Amazon Web Services (AWS), offering healthcare and life sciences developers the ability to build or customise digital biology models using proprietary data. This advancement could expedite computer-aided drug discovery by accelerating target identification, protein structure prediction, and drug candidate screening.
- NVIDIA’s BioNeMo, a generative AI platform for drug discovery, is now accessible via Amazon Web Services (AWS).
- The initiative was announced at AWS re:Invent and allows healthcare and life sciences developers to integrate NVIDIA-accelerated offerings into their AWS cloud resources.
- BioNeMo will be available on NVIDIA DGX Cloud on AWS and is currently accessible via AWS ParallelCluster and Amazon SageMaker.
- Techbio companies such as Alchemab Therapeutics, Basecamp Research, Character Biosciences, Evozyne, Etcembly and LabGenius are already using BioNeMo for AI-accelerated drug discovery and development.
- BioNeMo is a framework for digital biology generative AI, including pretrained large language models (LLMs), data loaders and optimised training recipes.
- It can help advance computer-aided drug discovery by speeding up target identification, protein structure prediction and drug candidate screening.
- One of the models, ESM-2, can be trained on 256 NVIDIA H100 Tensor Core GPUs, reducing training time from a month to a few days.
- BioNeMo’s pretrained models and optimised training recipes can help R&D teams explore more drug candidates, optimise lab experimentation and find promising clinical candidates faster.
